Showing 3271-3280 of 7015 results for "".
CKD-aP or Something Else? Decoding the Diagnosis
https://reachmd.com/programs/cme/ckd-ap-or-something-else-decoding-the-diagnosis/36296/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Mastering Mutation-Driven mCRC: From Testing to Targeted Therapy
https://reachmd.com/programs/cme/mastering-mutation-driven-mcrc-from-testing-to-targeted-therapy/32374/Explore expert recommendations for optimizing clinical outcomes with targeted treatment combinations in BRAF-mutant mCRC.Identifying the Impact of RSV in Adults
https://reachmd.com/programs/deep-breaths-updates-chest/identifying-the-impact-of-rsv-in-adults/15337/What measures need to be taken to reduce the risk of RSV infection? Explore further.Ocular Manifestations of Rheumatological Conditions
https://reachmd.com/programs/everyday-family-medicine/ocular-manifestations-of-rheumatological-conditions/10162/Dr. Anne Negrin elaborates on eye conditions an RA patient might present and how proper care coordination leads to better management.From Monoamines to Neurocircuits: Our Evolving Understanding of Depression
https://reachmd.com/programs/medical-industry-feature/monoamines-neurocircuits-understanding-depression/29735/Our understanding of depression has evolved over the past several decades, leading us to some potential new treatment options that focus on neuroplasticity, chemical imbalance, and negative cognitive biases. Learn more about the history of depression treatment approaches and the emerging concept ofRedefining First-Line Therapy in mCSPC: Applying Evidence in Practice
https://reachmd.com/programs/project-oncology/redefining-first-line-therapy-in-mcspc-applying-evidence-in-practice/49229/Treatment for metastatic castration-sensitive prostate cancer (mCSPC) has evolved significantly, moving beyond androgen deprivation therapy alone to more proactive combination approaches that can improve survival. Findings from key trials like CHAARTED, LATITUDE, and ARASENS have helped shape this sNew Medication for High Cholesterol Not Cost-Effective
https://reachmd.com/programs/the-jama-report/new-medication-high-cholesterol-not-cost-effective/8332/A new study in JAMA evaluated the cost-effectiveness of PCSK9 inhibitors and how increased use might affect the U.S. healthcare system.Testosterone Therapy Neither Advances Nor Slows Down Hardening of the Arteries in Older Men with Low Testosterone Levels
https://reachmd.com/programs/the-jama-report/testosterone-therapy-neither-advances-nor-slows-down-hardening-arteries-older-men-low-testosterone/7640/[Read the Article] The popularity of testosterone supplementation among older men has increased substantially over the past decade. However, the risks and benefits of long-term administration are still unclear. A new study examined whether using testosterone supplements affected the development of aExercise in CRC Survivors: A Closer Look at Biomarker Effects
https://reachmd.com/programs/project-oncology/exercise-in-crc-survivors-a-closer-look-at-biomarker-effects/49167/Journal of Cystic Fibrosis: Efficacy and Safety of Levofloxacin Inhalation Solution (APT-1026) in Stable Cystic Fibrosis Patients
https://reachmd.com/programs/Audioabstracts/journal-cystic-fibrosis-efficacy-safety-levofloxacin-inhalation-solution-apt-1026/8217/A study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients.